VolitionRx (NYSE-A:VNRX) told investors it has joined forces with Veterinary Pathology Group (VPG) to launch the Nu.Q Vet Cancer Test to veterinary practices in the UK and Ireland.
The NuQ Vet Cancer Test is a groundbreaking tool for the early detection and monitoring of cancer in dogs and VPG will be the first-to-market diagnostics laboratory in the UK to offer the test, the company said.
“It is a simple, non-invasive blood test that can easily integrate into preventive care plans,” commented Dr Tom Butera, CEO of Volition Veterinary Diagnostics Development.
“Veterinarians can run the test alongside routine blood work and imaging, to help provide earlier cancer detection, improve a dog's quality of life and give a better chance of effective treatment."
Volition noted that there are roughly 11 million dogs as pets in the UK, with 29% of households owning a dog. The Nu.Q Vet Cancer Test is an accessible and affordable screening tool for dogs with increased risk of developing cancer, such as older dogs, certain breeds with higher cancer prevalence rates and those dogs with familial history, it added.
”Our collaboration with Volition highlights the commitment of both organizations to improving the quality of life for pets and supporting veterinary professionals in their mission to provide the best possible care,” VPG CEO Fiona Gosling said.
"By integrating the revolutionary Nu.Q Vet Cancer Test into our diagnostic portfolio, we are expanding our wellness testing offering and empowering veterinarians with an accessible, cutting-edge tool to detect cancer in its early stages, ultimately leading to better outcomes and improved patient care.”
Volition is developing simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including cancer in both humans and animals.
Contact the author at stephen.gunnion@proactiveinvestors.com